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Summary The course of COPD has traditionally been equated with an accel-
erated decline in the forced expiratory volume in one second (FEV1) over time
in patients with COPD, compared to healthy individuals. However, other impor-
tant clinical outcomes associated with COPD also worsen over time and should
also be considered in conceptualizing the course of COPD. These include health
status, breathlessness related to activities of daily living, exercise capacity, the
frequency of exacerbations, and peripheral muscle weakness. These outcomes are
often quite responsive to therapy of COPD.
Presently there is no evidence that any treatment other than smoking cessation
can normalise the rate of decline of FEV1, and therefore be considered as modi-
fying the physiologic course of the disease. Thus, smoking cessation reigns as the
primary disease modifying strategy in COPD. Even though there are a number of
smoking cessation products on the market and smoking prevalence continues to
decrease marginally each year, more needs to be done to provide comprehensive
programmes to help people quit smoking. In the US in 2004, 37.5% of preventable
deaths were found to be tobacco-related.
The FEV1 does not reflect the clinical manifestations or the total burden of this
multidimensional illness. As novel therapeutic agents become available that may
alter the underlying pathology of COPD, additional markers and outcomes of
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disease progression will be needed to provide a more comprehensive assessment.
There has been increasing interest in predicting and assessing mortality as it is the
final outcome of disease progression.
In this review we have considered three approaches toward modifying the course
of COPD: smoking cessation, reduction in lung hyperinflation through medical and
surgical approaches, and long-term pharmacotherapy.
© 2008 Elsevier Ltd. All rights reserved.
Smoking cessation
Demographics --- the need
Presently, smoking cessation is the only intervention
shown to modify the physiologic course of COPD1,2.
There are 46 million smokers in the US and accord-
ing to the Department of Health and Human Ser-
vices, 1/3 of all tobacco users in that country will
die prematurely of tobacco-related disease3. In a
study published in 2004, 18% of total deaths in the
United States and 37.5% of preventable deaths in
the U.S. were found to be tobacco-related3. Since
the publication of the first surgeon general' s re-
port that linked tobacco use to illness and death,
cigarette smoking has continuously declined in the
US. Seventy percent of current smokers want to
quit4,5 and 80% have made at least one quit attempt
in their life6. Thirty five percent of smokers initiate
a quit attempt each year4---6 but despite the mar-
ket availability currently of seven effective smoking
cessation products representing three different drug
classes, only 2.5%5 are successful. Clearly there is
more work to be done.
Our previous failures
Nicotine polacrilex gum was introduced into the
market place as pharmacotherapy for cigarette ad-
diction 30 years ago7. Since that time, five other
nicotine replacement treatment (NRT) products and
bupropion (Zyban®) have come into the market
place. Each of these products had at the time of
launch into the market and continues to have sta-
tistically significant and clinically relevant efficacy.
Smoking cessation pharmacotherapies have enjoyed
instant and impressive gains in market share soon
after launch followed by precipitous declines in
sales despite their demonstrated efficacy. Some-
thing is missing in the use or marketing of nicotine
addiction pharmacotherapies.
Hope for new products like varenicline
Varenicline is an 4β2 nicotine acetylcholine receptor
partial agonist introduced into the market in 2006.
Results of two randomized, double blind placebo
and active treatment controlled studies8,9 revealed
impressive quit rates of 21.9 and 23.0% at 12 months
(Figure 1). In these two studies varenicline had
nearly significant (p = 0.057) and significantly (p=
0.004) greater abstinence rates than its active com-
parator, bupropion. While varenicline is an excit-
ing new addition to our arsenal of smoking cessa-
tion pharmacotherapies it is not without warts and
blemishes10.
Success of FDNY (New York Fire Department)
In 2006, a study was published entitled "Tobacco
Free with FDNY"11. In this study a highly moti-
vated population, FDNY members and their fami-
lies, were offered bupropion and nicotine replace-
ment products (patch, inhaler and nasal spray) in
conjunction with counseling for 3 months, free of
charge. Drug dosing was based on pretreatment
cigarette consumption and adjusted based on with-
drawal symptoms and adverse events. Captured
data included pretreatment Fagerstrom score and
biochemical or family member confirmed absti-
nence at 3, 6, and 12 months. A remarkable 37%
of participants were smoke free at 12 months11.
Enrollees required on average a greater number
of additional pharmacotherapies and dose of nico-
tine than predicted by pretreatment cigarette con-
sumption (Table 1). Treatment efficacy was di-
rectly proportional to pretreatment cigarette con-
sumption, a finding that is diametrically oppo-
site to previously published studies of nicotine
pharmacotherapies7. Abstinence rates correlated
inversely with tobacco dependency as measured by
the Fagerstrom score.
Other attempts at individualised therapy
Another study evaluated the efficacy of bupropion
treatment lasting 52 weeks12. Participants were
treated with open label bupropion for 7 weeks fol-
lowed by randomisation of all abstinent subjects to
an additional 45 weeks of bupropion or placebo and
followed for an additional 52 weeks after cessation
of treatment. The point prevalence of smoking ab-
stinence was significantly higher in the extended
bupropion treatment group than the placebo group
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Figure 1 Abstinence rates in 2 studies were significantly greater for varenicline vs. placebo at 1 year. In one of the
two studies varenicline was better than bupropion. 1 Gonzales D et al. JAMA. 2006;296:47---55; 2 Jorenby DE et al.
JAMA. 2006;296:56---63.
Table 1 “Tobacco Free With FDNY” Medication protocol with proposed treatment assignments based on
protocol (tobacco use alone) vs. actual regimen
Cigarettes
smoked per day
on study entry,
average no.
Daily medication regimen Enrollees
Based on
protocol alone
Actual
regimen
n (%) n (%)
1---5 Inhaler as needed (0---6 cartridges) 11 (5) 17 (6)
6---19 Inhaler as needed (0---6 cartridges) or patch (15 mg) while
awake
34 (15) 13 (6)
20---30 Inhaler as needed (0---12 cartridges) and patch (15 mg) while
awake
111 (50) 97 (44)
31---40 Inhaler as needed (0---12 cartridges) and patch (30 mg;
two patches) while awake
52 (24) 43 (20)
>40 Inhaler as needed (0---12 cartridges) and patch (30 mg;
two patches) and spray prn for immediate relief
12 (5) 44 (20)
Severe tobacco
cessation anxiety
Add bupropion SR (150 mg bid) to any of the above regimens 30 (14)
(55.1 vs 42.3%; p = 0.008) at the end of treatment
(52 weeks). Abstinence declined over time for both
groups (47.7 vs 37.7%, respectively at week 78; p =
0.034). At one year post active therapy the differ-
ence between the bupropion treated and placebo
groups was lost (abstinence of 41.6 and 40.0%, re-
spectively at week 104).
A similar design was utilised by Tonstad and col-
leagues when evaluating the safety and efficacy of
extended use varenicline13. Continuous abstinence
rates for weeks 13---52 were 43.6 and 36.9%, respec-
tively (p = 0.02). Continued follow up of this cohort
will provide information on the role of extended
therapy varenicline.
Need for creative approaches
The studies evaluating extended therapy with
bupropion and varenicline show that success rates
approaching 40% can be achieved12,13. These stud-
ies also highlight the importance of individualized
pharmacotherapy and coexistent prolonged counsel-
ing. The new varenicline (Chantix®) smoking cessa-
tion program combines pharmacotherapy with on-
line interactive computer-based behavioral counsel-
ing. Much has been written on this subject but lit-
tle that is published has long term cessation rates.
Etter and coworkers demonstrated a 2.6 fold in-
creased abstinence rate (5.8% vs 2.2%; p < 0.001) at
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7 months after entry into program using computer
generated personalised letters14. The advantage of
the intervention was lost at 24 months follow-up15.
Stretcher and colleagues evaluated the effi-
cacy web-based tailored vs. web-based non-tailored
behavioral support in conjunction with nicotine
patches. Continuous abstinence at 12 weeks was
22.8 vs 18.1% for tailored and non-tailored support
(p = 0.0006), respectively16 but no long term data is
yet published in this cohort.
The expense of web-based tailored behavioral
support is primarily in the set up of the system and
extended duration of use would add little to the
cost. If this modality proves efficacious and the ab-
stinence rates of long term face to face therapy is
translatable to this system perhaps lasting cessation
could be achieved on greater numbers of smokers at
a lesser cost.
Use of pharmacotherapy is not enough
Cigarette smoking prevalence dropped dramatically
after the publication of the first surgeons gen-
eral' s report on smoking and health (Figure 2). Since
that time prevalence rates have continued to de-
crease every year. Recently these changes have
been marginal17 and nearly 21% of Americans still
smoke. In a recent editorial18, 5 basic ways to help
smokers quit were listed. Providing cessation aids
such as NRT, bupropion and varenicline used in con-
junction with behavioral therapy was just one of
these five. The others were; 1) increase the price
of a pack of cigarettes, 2) ban smoking in public
places, 3) disseminate effective counter-marketing
messages about smoking and 4) ban tobacco ad-
vertising. State and local governments must work
with healthcare workers and insurers to provide a
comprehensive programme that includes all of the
above if smoking prevalence is to drop precipitously.
Figure 2 Smoking prevalence in 2004 was 20.1% but has
changed only 4.6% since 1995.
Modifying the course of COPD with medical
and surgical lung volume reduction surgery
There has been increasing interest in predicting and
assessing mortality, as it can be considered the final
outcome of disease progression. Accordingly, inter-
national guidelines have included “reducing mortal-
ity” as one of the goals of treatment of COPD.19---21
The following discussion deals with how medical and
surgical lung volume reduction might prolong sur-
vival.
Hyperinflation in COPD
Lung hyperinflation, manifested by an increased
lung volume at the end of expiration and an in-
creased residual volume, is usually present in COPD
patients when they are at rest, but is commonly
increased when they exercise. While a decreased
elastic recoil pressure is important as a cause of
resting hyperinflation, it has become clear that in
many patients with COPD, end-expiratory lung vol-
umes are also dynamically set. Based on the results
of five studies, approximately 48% of patients with
stable COPD have expiratory flow limitation (EFL)
during tidal breathing at rest22. As a result of EFL,
patients breathe at higher lung volumes (i.e., they
have lung hyperinflation). Breathing at higher vol-
umes permits expiratory flow to be increased and
reduces the resistive work of breathing, but this
is at the cost of a substantially increased elastic
work of breathing. A reduced inspiratory capacity
(IC), which is the maximal volume of air that can
be inhaled from the end of tidal breath, reflects
an elevation in ELV, or functional residual capac-
ity (FRC).
O' Donnell and colleagues23 reported that 80% of
105 patients who had severe COPD (FEV1 = 37 ±
13% predicted), resting hyperinflation (FRC = 174 ±
43% predicted), and a reduced diffusing capacity (57
± 21% predicted) exhibited dynamic hyperinflation
during cycle ergometry as defined by a decrease in
IC outside of 95% confidence limits. However, the
prevalence of dynamic hyperinflation is unknown in
patients with moderate airflow obstruction.
Hyperinflation causes shortening of the vertical
muscle fibers of the diaphragm, the development
of intrinsic positive end-expiratory pressure, and a
mechanical restriction with reduced tidal volume23.
These alterations have a deleterious effect on the
mechanics of breathing and contribute to breath-
lessness. With the increased respiratory rate that
occurs with exercise patients with COPD may de-
velop EFL and be unable to exhale completely.
As a result, they experience an increase in end-
expiratory lung volume. This development of dy-
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Figure 3 Proposed mechanisms whereby medical and
surgical lung volume reduction treatments might in-
crease survival in patients with chronic obstructive pul-
monary disease.
namic hyperinflation can be demonstrated by a re-
duction in IC as TLC remains constant.
Based on the pathophysiologic mechanisms de-
scribed above, it is expected that medical and sur-
gical interventions which reduce lung volumes (and
thereby reduce dyspnea) might also increase sur-
vival in patients with COPD. The rationale for this
speculation is:
a. A decreased inspiratory capacity / total lung ca-
pacity (IC/TLC) ratio and an increased residual
volume (RV) predict mortality in patients with
COPD; thus hyperinflation is related to mortality
in this disease.
b. Some COPD therapies can increase the IC or de-
crease the RV, indicating they have a lung volume
reduction effect.
c. Since hyperinflation predicts mortality indepen-
dent of airflow limitation, interventions that de-
flate the hyperinflated lung (as measured by an
increase in the IC/TLC and/or a decrease RV) very
possibly will prolong survival (Figure 3).
Theoretical support for this hypothesis is avail-
able from both animal and human studies. Exces-
sive stretch of the lung has been shown to pro-
mote inflammation and release of cytokines in ani-
mal models24. Moreover, strenuous resistive breath-
ing induces release of pro-inflammatory cytokines25.
In patients with adult respiratory distress syndrome
(ARDS) mechanical ventilation with lower tidal vol-
umes (6 ml/kg) (i.e., less inflation of the lung
parenchyma) has been shown to decrease mortal-
ity compared with use of traditional tidal volumes
(12 ml/kg)26.
Medical volume reduction
Four different medical interventions have been
shown to reduce lung volumes.
1. Bronchodilators
In placebo controlled trials, both short- (al-
buterol; ipratropium; oxitropium) and long-
acting bronchodilators (formoterol; salmeterol;
tiotropium) deflate the lung - as measured by an
increase in IC or by a corresponding decrease in
FRC27---33. These benefits can be observed at rest
and/or during exercise. For example, in a recent
study, O' Donnell and colleagues34 reported that the
combination of fluticasone priopionate (250 µg)
and salmeterol (50 µg) significantly reduced lung
hyperinflation at rest and during constant work
exercise after eight weeks of therapy compared
with placebo.
Not surprisingly, the benefits of medical volume
reduction with pharmacotherapy are greater in
those patients with greater degrees of static hyper-
inflation (i.e., hyperinflation demonstrated while
the patient is a rest). For example, Newton et al.31
reported greater changes in IC, RV, and FRC after
inhalation of albuterol in patients who had severe
hyperinflation (TLC > 133% predicted) compared to
those with moderate hyperinflation (115% predicted
< TLC < 133% predicted). DiMarco and colleagues35
found that the magnitude of the increase in IC after
four different bronchodilators was greater in those
patients (n = 12) with resting IC < 80% predicted
compared with patients (n = 8) who had IC > 80%
predicted. Boni et al.29 found that IC increased sig-
nificantly only in the 11 patients who had EFL, but
not in the nine patients who were non-flow limited.
2. Helium-oxygen mixture
As a low density gas, helium can reduce the re-
sistance drop associated with turbulent air flow.
Palange and colleagues36 reported that patients
with COPD (n = 12; FEV1 = 38 ± 10% predicted)
achieved increases in IC ( = 200 ml) at exercise
isotime, in peak VE ( = 2.8 l/min), and in exer-
cise endurance time ( = 4.8 min) when breathing
heliox (a mixture of 79% helium and 21% oxygen)
compared with room air. Adding to this information,
Eves and colleagues37 demonstrated that combining
helium and hyperoxia delayed dynamic hyperinfla-
tion and improved respiratory mechanics in 10 male
patients with COPD (FEV1 = 47 ± 17% predicted).
3. Oxygen
The inhalation of oxygen reduces ventilatory
drive (probably via peripheral chemoreceptors),
thereby decreases respiratory rate at iso-work
levels.38 This beneficial effect is seen even in COPD
patients without significant hypoxemia at rest or
during exercise. As stated earlier, higher respiratory
rates, such as from exercise, often lead to dynamic
hyperinflation in these patients. By promoting a
lower respiratory rate, oxygen therapy will allow
patients more time to exhale and empty the lungs,
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thereby reducing dynamic hyperinflation. Thus,
oxygen supplementation indirectly reduces lung
volumes in hyperinflated patients with COPD.
4. Rehabilitative exercise training
Porszasz and colleagues39 reported that patients
with COPD achieved decreases in minute ventila-
tion (VE,  = 2 l/min) and in respiratory frequency
( = 3 breaths/min) at exercise isotime after seven
weeks of high intensity exercise training compared
to pre-training results. This was accompanied by an
increase in IC ( = 130 ml) at isotime levels after
training. The latter indicates that exercise training
results in less ventilatory demand at identical work
levels, and this decreased ventilatory demand al-
lows for a lower respiratory rate and more time for
exhalation, thereby reducing lung volumes.
Lung Volume Reduction Surgery (LVRS)
The National Emphysema Treatment Trial (NETT) is
the largest investigation of LVRS. NETT compared
the effects of lung volume reduction surgery to
optimal medical care in 1,218 patients with se-
vere airflow limitation (post-bronchodilator FEV1 =
27 ± 7% predicted) and radiological evidence of
moderate-severe emphysema40. Severe hyperinfla-
tion was present with TLC of 128 ± 15 % predicted
and RV of 222 ± 49 % predicted. Physiologic features
including RV did not predict outcomes from surgery.
Although LVRS did not alter overall survival at two
years, differential risks and benefits were identified
in subgroups of subjects. Logistic regression analy-
ses demonstrated that two features were predictive
of survival --- distribution of emphysema and exer-
cise capacity. Subjects with upper lobe predominant
emphysema and low exercise capacity had better
survival after LVRS (risk ratio for death = 0.47; p =
0.005), whereas those with non-upper lobe predom-
inant emphysema and high exercise capacity had
a higher mortality after LVRS (risk ratio for death
= 2.06; p = 0.02)40. Longer term follow-up demon-
strated an overall survival advantage for all patients
who received LVRS compared with medical therapy
with a 5 year risk ratio for death of 0.86 (p = 0.02)41.
LVRS has also been shown to reduce dynamic hy-
perinflation during exercise testing42 and placement
of one-way valves in the airways has been shown to
reduce operating lung volumes at rest and dynamic
hyperinflation during exercise43.
In summary, measures of hyperinflation, such as
the IC/TLC ratio and RV, predict survival in patients
with COPD. Overdistension or stretch of the lung can
promote inflammation and lung injury based on an-
imal and human studies. At least three treatments:
oxygen therapy, lung volume reduction surgery, and
the combination of fluticasone/salmeterol, which
reduce hyperinflation at rest and/or during exer-
cise have been shown to improve survival in patients
with COPD.40,44,45 We propose that deflation of the
lung may be a mechanism whereby these interven-
tions prolong survival in COPD. Prospective testing
will be required to prove this.
Altering the course of COPD with current
pharmacotherapies
Bronchodilator therapy
Bronchodilators are the mainstay of current drug
therapy for COPD and are recommended by cur-
rent national and international guidelines as first-
line therapy in symptomatic patients and those who
demonstrate airflow limitation19,46,47. Three classes
of bronchodilators --- β2-agonists, anticholinergics,
and theophylline --- are currently available and can
be used individually or in combination (Table 2).
The use of short-acting bronchodilators is currently
advocated for relief of symptoms while that of in-
haled long-acting bronchodilators is recommended
as treatment of choice for maintenance therapy.
Bronchodilators work through their direct re-
laxation effect on airway smooth muscle cells,
although many have non-bronchodilator activities
which may contribute to their beneficial effects in
COPD48. The acute response to short-acting bron-
chodilators, does not predict long-term response to
maintenance therapy with long-acting agents; con-
sequently failure to respond to one group of bron-
chodilators does not necessarily reflect the response
to agents of the other groups49,50. The efficacy of
bronchodilators has traditionally been assessed by
the degree of improvement in FEV1. This, how-
ever, is seemingly at odds with the poor correlations
recognised between change of FEV1 and changes in
dyspnea or exercise performance.
An explanation of how symptoms may be
improved with bronchodilators, despite modest
changes in FEV1, is suggested by the closer corre-
lation of changes in lung volumes (such inspiratory
capacity (IC)) to dyspnea and exercise tolerance51.
Therefore, the assessment of bronchodilators using
indices of hyperinflation or air trapping may provide
a better indicator of efficacy52 than FEV1. Although
changes in lung volumes are independent of changes
in FEV1, several studies have demonstrated that
the more sustained airway patency offered by long-
acting bronchodilators reduces air trapping53,54.
Currently available long-acting bronchodilators
have been shown to have significant effects in
the long-term management of COPD. The two
currently available LABAs --- salmeterol and for-
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Table 2 Commonly used pharmacotherapies in
COPD
β2-agonists
Short-acting Bitolterol
Clenbuterol
Fenoterol
Isoetharine
Levalbuterol
Metaproterenol
Pirbuterol
Salbutamol (albuterol)
Terbutaline
Long-acting Bambuterol
Formoterol
Salbutamol (albuterol) SR
Salmeterol
Terbutaline SR
Anticholinergics
Short-acting Ipratropium bromide
Oxitropium bromide
Long-acting Tiotropium
Combination short-acting β2-agonists plus
anticholinergic in one inhaler
Fenoterol/Ipratropium
Salbutamol/Ipratropium
Methylxanthines
Aminophylline
Bamiphylline
Dyphylline
Theophylline (SR)
Inhaled glucocorticosteroids
Beclomethasone
Budesonide
Ciclesonide
Flunisolide
Fluticasone
Mometasone
Triamcinolone
Combination long-acting β2-agonists plus inhaled
glucocorticosteroids in one inhaler
Formoterol/budesonide
Salmeterol/fluticasone
moterol --- have been shown to significantly im-
prove lung function, health status, and symptom
reduction, compared with both placebo53,55---57 and
ipratropium58,59. The long-acting muscarinic recep-
tor antagonist tiotropium also shows significant im-
provements in lung function, dyspnoea, exercise
tolerance, and health related quality of life in pa-
tients with COPD, relative to placebo32,60,61 and
ipratropium62. Two more recent studies, specifically
designed to explore the potential differences be-
tween tiotropium and salmeterol, seem to indicate
a greater efficacy of tiotropium than this LABA63,64.
The use of LABAs and tiotropium have also been
shown to decrease the number of exacerbations and
time to first exacerbation of COPD65.
In addition to their prolonged bronchodila-
tion effect, some bronchodilators have other non-
bronchodilator activities that may potentiate their
beneficial effects in the treatment of COPD. LABAs
exert several effects that may be of clinical
relevance48. These include inhibition of airway
smooth muscle cell proliferation and inflammatory
mediator release, as well as non smooth-muscle
effects, such as stimulation of mucociliary trans-
port, cytoprotection of the respiratory mucosa, and
attenuation of neutrophil recruitment and activa-
tion. However, many of these effects have only
been described in vitro and in animal studies. Theo-
phylline has also been shown to exert several non-
bronchodilator effects which may enhance its ef-
fects in COPD66. None of the currently available
bronchodilators has yet been shown to alter the nat-
ural history of COPD over time. However, a large
prospective multinational study, the UPLIFT study,
is currently underway to investigate the long-term
effect of tiotropium on the decline of lung function
in patients with COPD67.
Bronchodilator combination therapy
For patients whose conditions are not sufficiently
controlled with bronchodilator monotherapy, cur-
rent guidelines recommend combining medications
of different classes, in particular an inhaled anti-
cholinergic with a β2-agonist, which seems to be a
convenient way of delivering treatment and obtain-
ing better results19,46,47. Cell signalling through mus-
carinic M3 receptors in airway smooth muscle cells
is well detailed at a molecular level, and is distinct
to those of β2-agonists68,69. Thus, there is potential
for the two drugs to combine additively. Moreover,
it has been documented that β2-adrenoceptors also
mediate inhibition of cholinergic neurotransmission
in isolated bovine trachea, through a mechanism
involving activation of KCa channels rather than
adenylyl cyclase70. It is not a surprise, therefore,
that large studies have demonstrated that the com-
bination of the short-acting β2-agonist salbutamol
with the short-acting anticholinergic ipratropium is
superior to either single agent alone71. More re-
cently, some trials have highlighted that LABAs may
represent the most effective option for combination
therapy with an anti-muscarinic agent72.
Considering that formoterol provides a greater
degree of early bronchodilation (in the first 2 hours)
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than tiotropium and comparable bronchodilation
over 12 hours73, the bronchodilator effect of sin-
gle doses of formoterol 12 µg and tiotropium 18 µg,
and formoterol 12 µg + tiotropium 18 µg given to-
gether was examined in stable COPD74. Formoterol
and tiotropium appeared complementary. In fact
tiotropium ensured prolonged bronchodilation and
formoterol added fast onset and greater peak ef-
fect. Unfortunately, patients only received a sin-
gle dose of formoterol even though FEV1 was mea-
sured over 24 hours. Combination treatment demon-
strated numerical but not statistically significant
differences compared with the single treatments
and this is likely because the study was underpow-
ered to show a significant difference between treat-
ments. Another study, which investigated the poten-
tial additive effect of a second long-acting bron-
chodilator in patients receiving a first long-acting
bronchodilator75, showed that the additive effect
does not depend on which type of bronchodilator
is administered first.
In a third study, the administration of single doses
of 18 µg tiotropium, 50 µg salmeterol, or 18 µg
tiotropium + 50 µg salmeterol supported the pos-
sibility of combining tiotropium and salmeterol in
patients suffering from stable COPD, but excluded
the once-daily co-administration of the two drugs76.
It was also observed that the onset of action of the
two drugs was faster when they were combined con-
sidering that both agents have a slow onset of ac-
tion.
More recently, van Noord et al.77 explored the
effects elicited by 6 weeks of treatment with
tiotropium 18 µg once-daily in the morning, for-
moterol 12 µg twice a day, and tiotropium 18 µg
+ formoterol 12 µg once-daily in the morning in
patients suffering from moderate-to-severe COPD.
Patients receiving combination treatment had a
greater improvement in FEV1 and FVC compared
with those receiving the individual agents over 24 h.
Significantly better improvements in morning and
evening PEF and daytime (but not night-time) res-
cue salbutamol use were also observed.
A more recently completed clinical trial, which
enrolled 847 patients with stable COPD treated
for 24 weeks with formoterol 10 µg twice
a day, tiotropium 18 µg once-daily, tiotropium
plus formoterol or placebo, showed that for se-
lected endpoints (speed of onset of bronchodila-
tion), formoterol plus tiotropium combination ther-
apy was significantly more effective than either
monotherapy78. For some variables (notably, FEV1
2 hours post-dose, and exacerbations needing addi-
tional treatment), combination therapy showed an
advantage which was not statistically significant.
For many efficacy variables in the study (e.g. b`ad
days' and e`xacerbation days' from diary symptoms,
symptom-free days, symptom scores, quality of life
[QoL]), the combination and monotherapies were
not significantly different.
Furthermore, it has also been documented that
for patients suffering a mild-to-moderate acute ex-
acerbation of COPD, combination therapy with for-
moterol and tiotropium may provide faster and
greater peak and overall bronchodilation, with im-
provement in oxygen saturation79. In this study, both
single agents had a shorter duration than expected,
perhaps because of increased airways inflammation
during an exacerbation --- however, the combination
improved FEV1 for 24 h. Further studies are needed
to explore the use of these agents in acute exacer-
bations of COPD.
LABA + inhaled corticosteroid combination
therapy
The physiologic and clinical benefits of LABAs
have been shown to be enhanced when adminis-
tered in conjunction with inhaled corticosteroids
(ICS)80. LABA and ICS combination products have
been shown to improve lung function, symptoms,
health status and reduce exacerbations in patients
with moderate to severe COPD. The recently com-
pleted three year TORCH study is the first study to
demonstrate a long-term benefit of pharmacother-
apy in COPD patients.45 The combination of sal-
meterol/fluticasone propionate had a 17.5% rela-
tive risk reduction of mortality compared to placebo
(p=0.052). This effect, although of borderline statis-
tical significance, is clinically important and compa-
rable to that of statins in chronic heart disease and
smoking cessation in COPD. In addition to a clinically
important effect on mortality, the combination of
salmeterol/fluticasone propionate significantly de-
creased exacerbations moderate and severe exacer-
bations (25% annual reduction of moderate to severe
exacerbations, NNT= 4, P<0.001), improved quality
of life and function compared to placebo and its
components, salmeterol and fluticasone propionate
given as monotherapy.
An intriguing short term trial (6-week treat-
ment) has shown that combination therapy with
formoterol and tiotropium provides superior bron-
chodilator effects measured by post-medication
FEV1 than combined treatment with salmeterol and
an ICS81. However, another study has documented
that the improvement in pulmonary function, ex-
pressed as a change in FEV1, did not differ be-
tween tiotropium and salmeterol/fluticasone propi-
onate, while the simultaneous administration of the
two treatments provided superior improvements in
trough FEV1 compared to therapy with the other
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two therapeutic regimens given alone82. This is an
interesting finding, but current data do not allow to
establish whether the improvements in lung func-
tion demonstrated by combining fluticasone propi-
onate/salmeterol and tiotropium in severe-to-very
severe COPD was linked to the effect of the com-
bination of two long acting bronchodilators or due
to a synergistic interaction between the ICS and the
long acting bronchodilators.
Safety of current therapy in COPD
The long-term safety (>3 years) of currently used
long-acting bronchodilators needs further studies,
however short-term studies (<1 year) have con-
sistently demonstrated the safety of these agents
when used within their approved dosage83. While
the safety of long-acting β2-agonists as monother-
apy in asthma has recently been questioned84, the
use of these medications in COPD has generally been
described as safe. More recently, data from the re-
cently completed TORCH study, confirms the safety
of the chronic use of salmeterol as monotherapy in
COPD over three years45. Nevertheless, β-agonists
should be used with caution in patients with un-
derlying cardiac disorders including ischemic heart
disease85. Anticholinergic agents should also be used
with caution in patients with bladder neck obstruc-
tion due to prostatism, and patients with glaucoma.
The long-term safety of tiotropium over 4 years
is being investigated in the UPLIFT study which
is currently underway67. A recent meta-analysis86,
which included randomized controlled trials of at
least 3 months duration that evaluated anticholin-
ergic or β2-agonist use compared with placebo or
each other in patients with COPD, documented that
while inhaled anticholinergics significantly reduced
severe exacerbations and respiratory deaths in pa-
tients with COPD, β2-agonists were associated with
an increased risk for respiratory deaths. However,
as highlighted by the authors themselves, this meta-
analysis had several limitations, the fact that limits
the validity of its results. The long-term safety of in-
haled corticosteroids in COPD given over three years
was also recently evaluated in the TORCH trial.
While the incidence of adverse effects of inhaled
corticosteroids on the bone, eye and other systems
were not higher than those seen in the placebo
treated patients, there was a reported increased in-
cidence of pneumonia. This observation needs to be
further evaluated in future studies.
Future directions
Bronchodilators are still central in the symptomatic
management of COPD. For this reason, the current
opinion is that it will be advantageous to develop
inhalers containing combination of several classes
of long-acting bronchodilator drugs in an attempt to
simplify treatment regimes as much as possible. The
investigational therapies for COPD discussed above
have shown promising results. It is likely that the
development of once-daily dual-action ultra LABA
+ LAMA combination products may serve as a basis
for improved ' triple therapy' combinations through
co-formulation with novel ICS. In the light of the re-
sults of the TORCH study45, we believe that a triple
once-daily combination of LABA, LAMA and ICS might
bring a real advantage over the existing therapies
for patients with COPD.
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